Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Bruch, PM; Dietrich, S; Finel, H; Boumendil, A; Greinix, H; Heinicke, T; Bethge, W; Beelen, D; Schmid, C; Martin, H; Castagna, L; Scheid, C; Schafer-Eckart, K; Bittenbring, J; Finke, J; Sengeloev, H; Heiblig, M; Cornelissen, J; Chevallier, P; Mohty, M; Robinson, S; Montoto, S; Dreger, P.
Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters
LEUKEMIA. 2023; Doi: 10.1038/s41375-022-01782-z
Web of Science PubMed FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Greinix Hildegard

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is a rare myeloid malignancy with a generally poor prognosis. Although preliminary evidence suggests that hematopoietic cell transplantation (HCT) could improve outcome in patients with BPDCN, the individual contributions of conditioning and graft-versus-tumor (GVT) effects to HCT success are undefined. We present a retrospective study of 162 adult patients who underwent a first HCT (allogeneic 146, autologous 16) between 2009 and 2017, and were registered with the EBMT. Median age was 57 (range 20-73) years, and disease status at HCT was first complete remission (CR1) in 78%. Among patients receiving allogeneic HCT (alloHCT), myeloablative conditioning (MAC), reduced intensity conditioning (RIC) and in-vivo T-cell depletion (TCD) were used in 54%, 46%, and 59% respectively. Total body irradiation (TBI) was the conditioning backbone in 61% of MAC and 26% of RIC transplants. One-year overall survival (OS) and progression-free survival (PFS) rates were comparable after alloHCT and autologous HCT (autoHCT). Among alloHCT recipients, MAC with TBI significantly improved OS and PFS, independently of CR1, age, Karnofsky index and TCD. Accordingly, MAC (ideally based on TBI) should be preferred for alloHCT recipients with BPDCN. In patients who are not elegible for MAC alloHCT, autoHCT could be considered.

© Med Uni Graz Impressum